MedTrace Logo

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

NCT00070473 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2014-02-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed disodium in treating young patients with recurrent solid tumors.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

pemetrexed disodium

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • H. Stacy Nicholson, MD, MPH · OHSU Knight Cancer Institute

  • Linda C. Stork, MD · Doernbecher Children's Hospital at Oregon Health and Science University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-03-31
Completion
2008-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00070473 on ClinicalTrials.gov